Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease
Low high-density lipoprotein-cholesterol (HDL-c) is the most remarkable lipid trait both in mild-to-moderate chronic kidney disease (CKD) patients as well as in advanced renal disease stages, and we have previously shown that reduced lecithin:cholesterol acyltransferase (LCAT) concentration is a maj...
Main Authors: | Andrea Baragetti, Alice Ossoli, Arianna Strazzella, Sara Simonelli, Ivano Baragetti, Liliana Grigore, Fabio Pellegatta, Alberico L. Catapano, Giuseppe Danilo Norata, Laura Calabresi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/7/2289 |
Similar Items
-
High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis
by: Alice Ossoli, et al.
Published: (2016-06-01) -
Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort
by: Chiara Pavanello, et al.
Published: (2020-12-01) -
Effects of natural mutations in lecithin:cholesterol acyltransferase on the enzyme structure and activity
by: F. Peelman, et al.
Published: (1999-01-01) -
Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity
by: John K. Bielicki, et al.
Published: (1999-05-01) -
Evidence for altered positional specificity of LCAT in vivo
by: Papasani V. Subbaiah, et al.
Published: (2004-12-01)